Pacira BioSciences, Inc. 10-Q

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK The primary objective of our cash equivalents and investment activities is to preserve principal while at the same time maximizing the income that we receive from our investments without significantly increasing risk. We invest in corporate bonds, commercial paper, asset-backed securities and U.S. Treasury and other government agency notes for purposes other than trading which are reported at fair value. These securities are subject to interest rate risk and credit risk. This means that a change in prevailing interest rates may cause the fair value of the investment to fluctuate. For example, if we hold a security that was issued with a fixed interest rate at the then-prevailing rate and the interest rate later rises, we expect that the fair value of our investment will decline. A hypothetical 100 basis point increase in interest rates would have reduced the fair value of our available-for-sale securities at June 30, 2025 by approximately $0.3 million. The fair value of our 2025 Notes was impacted by both the fair value of our common stock and interest rate fluctuations. As of June 30, 2025, the estimated fair value of the 2025 Notes was $993 per $1,000 principal amount. See Note 9, Debt , to our condensed consolidated financial statements included herein for further discussion of our 2025 Notes, which bore interest at a fixed rate. At June 30, 2025, $202.5 million of principal remained outstanding on the 2025 Notes. On August 1, 2025, the 2025 Notes matured and we settled the remaining outstanding principal balance of $202.5 million cash. For more information, see Note 18, Subsequent Events. The fair value of our 2029 Notes is impacted by both the fair value of our common stock and interest rate fluctuations. As of June 30, 2025, the estimated fair value of the 2029 Notes was $979 per $1,000 principal amount. See Note 9, Debt , to our condensed consolidated financial statements included herein for further discussion of our 2029 Notes, which bear interest at a fixed rate. At June 30, 2025, $287.5 million of principal remains outstanding on the 2029 Notes. The TLA Term Loan provided for a single-advance term loan in the principal amount of $150.0 million and was scheduled to mature on March 31, 2028. Each term loan borrowing that was a term benchmark borrowing or daily simple SOFR borrowing bore interest at a rate per annum equal to (i) the Adjusted Term SOFR Rate or Adjusted Daily Simple SOFR (as each is defined in the TLA Credit Agreement), plus (ii) a spread based on our Senior Secured Net Leverage Ratio ranging from 3.00% to 3.75%. At June 30, 2025, the outstanding principal on the TLA Term Loan was $98.8 million. As of June 30, 2025, borrowings under the TLA Term Loan consisted entirely of term benchmark borrowings at a rate of 7.43%. In July 2025, we repaid the indebtedness outstanding under our TLA Credit Agreement and terminated the TLA Credit Agreement concurrently with our entry into the new Revolving Credit Facility. For more information, see Note 18, Subsequent Events . We have agreements with certain vendors and partners that operate in foreign jurisdictions. The more significant transactions are primarily denominated in the U.S. Dollar, subject to an annual adjustment based on changes in currency exchange rates. Pacira BioSciences, Inc. | Q2 2025 Form 10-Q | Page 55 Table of Contents Additionally, our accounts receivable are primarily concentrated with four large wholesalers of pharmaceutical products. In the event of non-performance or non-payment, there may be a material adverse impact on our financial condition, results of operations or net cash flow.